Meeting
2022 ASCO Genitourinary Cancers Symposium
Tivozanib (T) as first-line (1L) treatment of metastatic renal cell carcinoma (mRCC): A real-world outcome review in North-West of England (NWE), UK.
Authors
Jonathan Heseltine
Clatterbridge Cancer Centre, Wirral, United Kingdom
Jonathan Heseltine , Jennifer Allison , Sam Wong , Kellati Prasad , Helen Wong , Zhu Oong , Natalie Charnley , Andrea Law , Omi Parikh , Manon Rhys Pillai , Tom Waddell , Richard Griffiths , Shien Chow
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 335)
DOI
10.1200/JCO.2022.40.6_suppl.335
Abstract #
335
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Tivozanib as first-line treatment of metastatic renal cell carcinoma: A real-world outcome review in North-West of England, United Kingdom.
First Author: Sam Wong
Poster
2023 ASCO Genitourinary Cancers Symposium
Estimated cost of adverse event (AE) management for patients (pts) with metastatic renal cell carcinoma (mRCC) treated with a VEGFR TKI.
First Author: Jeffrey Thomas Yorio
Poster
2021 Genitourinary Cancers Symposium
Axitinib and avelumab (AA) as first-line treatment of metastatic renal cell carcinoma (mRCC): A real-world outcome review in the Northwest of England, United Kingdom.
First Author: Jennifer Allison
Poster
2020 ASCO Virtual Scientific Program
TIVO-3: Final OS analysis of a phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with metastatic renal cell carcinoma (RCC).
First Author: Sumanta K. Pal